...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergology international: official journal of the Japanese Society of Allergology >Intranasal administration of IL-35 inhibits allergic responses and symptoms in mice with allergic rhinitis
【24h】

Intranasal administration of IL-35 inhibits allergic responses and symptoms in mice with allergic rhinitis

机译：鼻内注射IL-35抑制过敏性鼻炎小鼠的过敏反应和症状

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background IL-35 was recently identified as an anti-inflammatory cytokine. We previously reported that recombinant fusion protein of murine IL-35 and human IgG1 Fc fragment (rIL-35) reduced Th2 cytokines (IL-4 and IL-5) in?vitro. However, it is unclear whether IL-35 can attenuate nasal allergic responses and symptoms of allergic rhinitis in?vivo. Methods To investigate the in?vivo effect of IL-35 on allergic rhinitis in mice, mice were sensitized with ovalbumin (OVA). Intranasal administration of rIL-35 and intranasal challenge of OVA were then performed. Nasal symptoms were estimated after the last nasal challenge. Nasal tissue and cervical lymph nodes (CLN) were collected. OVA-specific IgE in sera, OVA-specific T cell response, and the production of cytokines (IL-4, IL-5, and IL-10) stimulated by the OVA antigen were measured. The transcription level of Foxp3 and the frequency of CD4 + CD25 + regulatory T cells were also measured. Results rIL-35 significantly inhibited the number of sneezes and nasal rubbing movements. It also reduced the number of eosinophils in the nasal mucosa and significantly decreased the level of OVA-specific IgE, the OVA-specific T cell proliferation, and the production of IL-4 and IL-5. Furthermore, rIL-35 significantly increased the production of IL-10, the transcription level of Foxp3, and the frequency of CD4 + CD25 + regulatory T cells. Conclusions This study showed for the first time that rIL-35 inhibits nasal allergic responses and symptoms in mice, and that rIL-35 increases IL-10, Foxp3, and CD4 + CD25 + regulatory T cells in CLN. This study also suggests that intranasal administration of IL-35 can attenuate allergic rhinitis. Graphical abstract Display Omitted.
机译：背景IL-35最近被鉴定为抗炎细胞因子。我们先前曾报道鼠IL-35和人IgG1 Fc片段（rIL-35）的重组融合蛋白在体外能降低Th2细胞因子（IL-4和IL-5）。然而，目前尚不清楚IL-35是否能减轻鼻腔过敏反应和体内变应性鼻炎的症状。方法为了研究IL-35对小鼠变应性鼻炎的体内作用，用卵清蛋白（OVA）致敏小鼠。然后进行rIL-35的鼻内给药和OVA的鼻内激发。在最后一次鼻刺激后估计鼻症状。收集鼻组织和宫颈淋巴结（CLN）。测量血清中OVA特异性IgE，OVA特异性T细胞反应以及OVA抗原刺激的细胞因子（IL-4，IL-5和IL-10）的产生。还测量了Foxp3的转录水平和CD4 + CD25 +调节性T细胞的频率。结果rIL-35显着抑制了打喷嚏次数和鼻摩擦动作。它还减少了鼻粘膜中的嗜酸性粒细胞的数量，并显着降低了OVA特异性IgE的水平，OVA特异性T细胞的增殖以及IL-4和IL-5的产生。此外，rIL-35显着增加了IL-10的产生，Foxp3的转录水平以及CD4 + CD25 +调节性T细胞的频率。结论这项研究首次显示rIL-35抑制小鼠的鼻变态反应和症状，rIL-35增加CLN中的IL-10，Foxp3和CD4 + CD25 +调节性T细胞。这项研究还表明，鼻腔注射IL-35可以减轻过敏性鼻炎。图形抽象显示被忽略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号